Company Profile

AcryMed Inc
Profile last edited on: 3/8/19      CAGE: 05XU1      UEI:

Business Identifier: Pain management and infusion therapy: infection and wound care
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9560 SW Nimbus Avenue
Beaverton, OR 97008
   (503) 624-9830
Location: Single
Congr. District: 01
County: Washington

Public Profile

In January 2008, AcryMed Inc was acquired by I-Flow Corp. of Lake Forest, CA. The following year - 2009 - I-flow was acquired by Kimberley Clark Healthcare - since renamed Halyard - itself now part of Owens & Minor,. AcryMed had been focused on the introduction of novel medical products that help heal wounds or reduce infections: products comingout of from its proprietary technologies through clinical investigation, regulatory clearance, and manufacturing development. The firm's stratgey had been to seek marketing partners around the world to sell and distribute AcryMed's products. while in some instances licenses its technologies to companies that want to enhance their own products. The company developed a proprietary skin substitute material branded Microlattice®: foundation for the company's first commercial product, an advanced moist wound care dressing marketed initially under the AcryDerm brand and then in the U.S. by Smith & Nephew under the FlexiGel® brand. If the wound too dry product donates moisture; too wet it absorbs excess moisture to provide a healthy environment for healing wounds. In addition to this moisture management capability, Microlattice matrix is also an optimal vehicle to deliver active agents to the body over an extended time. A wide range of active agents have successfully been integrated into Microlattice to produce devices that deliver therapeutically significant quantities of agents ranging from elemental oxygen to protein growth factors. The first commercially available products using this approach are the SilvaSorb® silver antimicrobial dressings and gel which incorporate AcryMed's proprietary stabilized silver chemistry

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $130,453
Project Title: Retinoids as Novel Treatment of Ischemic Stroke
2006 1 NIH $143,706
Project Title: Silver coatings to combat catheter associated infections
2005 2 NIH $835,926
Project Title: Novel Antimicrobial Treatment In Burn Graft Biomaterials
2002 2 NIH $993,174
Project Title: On Demand Antimicrobial Iodine In A Wound Contact Matrix
2001 1 NIH $120,305
Project Title: Entrapment Of 02 In A Semi-Solid For Hypoxic Wounds

Key People / Management

  Jack McMaken -- President

  John A Calhoun -- Chief Financial Officer

  Bruce L Gibbins -- Chief Technical Officer

  David Rardin -- Vice President, Marketing & Business Development

Company News

There are no news available.